

**CY 2015 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals  
As of December 31, 2015**

This report reflects the data shown as it is identified in the database

**Selection Criteria:**

**User Response: Start Date: 1/1/2015 End Date: 12/31/2015**

**Sort Order: Approval Date**

APPL NUMBER	SUBM TYPE & NUMBER	SUPPLEMENT TYPE or SUBMISSION CLASS CODE	ESTABLISHED NAME	APPLICANT	PRIORITY REVIEW	RECEIPT DATE	APPROVAL DATE	TOTAL APPROVAL TIME (MONTHS)
NDA 020986	78	New Patient Population	INSULIN ASPART RECOMBINANT	NOVO NORDISK INC	S	3/14/2014	1/14/2015	10.1
NDA 021152	4	New Patient Population	FLUTICASONE PROPIONATE	FOUGERA PHARMACEUTICALS INC	S	7/18/2014	1/16/2015	6.0
NDA 022068	20	Accelerated Approval Confirmatory Study	NILOTINIB	NOVARTIS PHARMACEUTICALS CORP	S	3/28/2014	1/27/2015	10.0
NDA 021251	47	New Patient Population	LOPINAVIR; RITONAVIR	ABBVIE INC	S	3/31/2014	1/28/2015	10.0
NDA 021906	40	New Patient Population	LOPINAVIR; RITONAVIR	ABBVIE INC	S	3/31/2014	1/28/2015	10.0
NDA 205552	2	New Patient Population	IBRUTINIB (PCI-32765)	PHARMACYCLICS INC	P	10/17/2014	1/29/2015	3.4
NDA 021977	37	New Indication	LISDEXAMFETAMINE DIMESYLATE	SHIRE DEVELOPMENT INC	P	8/1/2014	1/30/2015	6.0
NDA 019537	83	New Indication	CIPROFLOXACIN HYDROCHLORIDE	BAYER HEALTHCARE PHARMACEUTICALS INC	S	4/2/2014	2/2/2015	10.1
NDA 019847	55	New Indication	CIPROFLOXACIN	BAYER HEALTHCARE PHARMACEUTICALS INC	S	8/5/2014	2/2/2015	6.0
NDA 019857	63	New Indication	CIPROFLOXACIN	BAYER HEALTHCARE PHARMACEUTICALS INC	S	4/2/2014	2/2/2015	10.1
NDA 020780	41	New Indication	CIPROFLOXACIN	BAYER HEALTHCARE PHARMACEUTICALS INC	S	4/2/2014	2/2/2015	10.1
NDA 021880	41	New Indication	AZACITIDINE AND LENALIDOMIDE	CELGENE CORP	S	4/22/2014	2/17/2015	9.9
NDA 022203	10	New Patient Population	AZELASTINE HCL	MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC	P	9/24/2014	2/20/2015	4.9
NDA 022203	11	New Patient Population	AZELASTINE HCL	MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC	P	9/24/2014	2/20/2015	4.9
NDA 202236	8	New Patient Population	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPRIONATE	MEDA PHARMACEUTICALS INC	P	8/22/2014	2/20/2015	6.0
NDA 201699	9	Pediatric	FIDAXOMICIN	CUBIST PHARMACEUTICALS INC	P	11/13/2014	2/24/2015	3.4
NDA 021730	36	Pediatric	LEVALBUTEROL TARTRATE HFA INHALATION AER	SUNOVION PHARMACEUTICALS INC	S	5/27/2014	3/12/2015	9.5
NDA 022117	18	Pediatric	ASENAPINE	FOREST LABORATORIES LLC	P	9/24/2014	3/12/2015	5.6
NDA 022117	19	Pediatric	ASENAPINE	FOREST LABORATORIES LLC	P	9/12/2014	3/12/2015	6.0
NDA 022567	12	New Dosing Regimen	DOCUSATE SODIUM 100MG/SIMETHICONE 125MG FIXED DOES COMBINATION	FOREST LABORATORIES LLC	S	5/16/2014	3/16/2015	10.0
NDA 020564	33	Pediatric	LAMIVUDINE TABLETS	VIIV HEALTHCARE CO	S	5/23/2014	3/23/2015	10.0
NDA 020596	32	Pediatric	LAMIVUDINE ORAL SOLUTION	VIIV HEALTHCARE CO	S	5/23/2014	3/23/2015	10.0
NDA 020977	27	Pediatric	ABACAVIR SULFATE	VIIV HEALTHCARE CO	S	5/23/2014	3/23/2015	10.0
NDA 020978	31	Pediatric	ABACAVIR SULFATE	VIIV HEALTHCARE CO	S	5/23/2014	3/23/2015	10.0
NDA 205122	1	New Indication	TOPIRAMATE EXTENDED RELEASE CAPSULES	UPSHER-SMITH LABORATORIES INC	S	5/30/2014	3/30/2015	10.0
NDA 021304	11	Pediatric	VALGANCICLOVIR HYDROCHLORIDE	HOFFMANN-LA ROCHE INC	S	3/31/2014	4/23/2015	12.8

# CY 2015 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals As of December 31, 2015

This report reflects the data shown as it is identified in the database

**Selection Criteria:**

**User Response: Start Date: 1/1/2015 End Date: 12/31/2015**

**Sort Order: Approval Date**

NDA 022257	5	Pediatric	VALGANCICLOVIR HYDROCHLORIDE	HOFFMANN-LA ROCHE INC	S	3/31/2014	4/23/2015	12.8
NDA 204026	6	New Indication	POMALIDOMIDE	CELGENE CORP	S	6/30/2014	4/23/2015	9.8
NDA 204275	1	New Dosing Regimen	BREO ELLIPTA	GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE	S	6/30/2014	4/30/2015	10.0
NDA 021085	60	Animal Rule Confirmatory Study	MOXIFLOXACIN HCL	BAYER HEALTHCARE PHARMACEUTICALS INC	S	7/8/2014	5/8/2015	10.0
NDA 021277	56	Animal Rule Confirmatory Study	MOXIFLOXACIN HYDROCHLORIDE IN NACL INJECTION	BAYER HEALTHCARE PHARMACEUTICALS INC	S	7/8/2014	5/8/2015	10.0
NDA 021926	12	Pediatric	SUMATRITAM/NAPROXEN	PERNIX IRELAND LTD	P	11/14/2014	5/14/2015	6.0
NDA 020241	53	New Patient Population	LAMOTRIGINE	GLAXOSMITHKLINE LLC	S	7/18/2014	5/18/2015	10.0
NDA 020764	46	New Patient Population	LAMOTRIGINE	GLAXOSMITHKLINE LLC	S	7/18/2014	5/18/2015	10.0
NDA 022251	17	New Patient Population	LAMICTAL ODT	GLAXOSMITHKLINE LLC	S	7/18/2014	5/18/2015	10.0
NDA 019651	25	Pediatric	MESALAMINE 1 G TABLETS	WARNER CHILCOTT COMPANY LLC	S	7/31/2014	5/27/2015	9.9
NDA 021361	12	New Indication	RIFAXIMIN	SALIX PHARMACEUTICALS INC	P	8/29/2014	5/27/2015	8.9
NDA 021083	55	New Indication	SIROLIMUS	PF PRISM CV	P	12/23/2014	5/28/2015	5.1
NDA 021110	73	New Indication	SIROLIMUS	PF PRISM CV	P	12/23/2014	5/28/2015	5.1
NDA 021704	17	New Indication	ALLEGRA D	SANOVI-AVENTIS US LLC	S	8/8/2014	6/8/2015	10.0
NDA 022291	15	Pediatric	ELTROMBOPAG	NOVARTIS PHARMACEUTICALS CORP	P	12/19/2014	6/11/2015	5.7
NDA 021450	8	Pediatric	ZOLMITRIPTAN NASAL SPRAY 0.5/2.5/5 MG	IPR PHARMACEUTICALS INC	S	8/14/2014	6/12/2015	9.9
NDA 202834	5	New Indication	PERAMPANEL 0.5MG/ML SUSPENSION	EISAI INC	S	8/19/2014	6/19/2015	10.0
NDA 021226	40	Pediatric	LOPINA VIR; RITONAVIR	ABBVIE INC	S	9/17/2014	6/26/2015	9.3
NDA 021251	49	Pediatric	LOPINA VIR; RITONAVIR	ABBVIE INC	S	9/17/2014	6/26/2015	9.3
NDA 021906	42	Pediatric	LOPINA VIR; RITONAVIR	ABBVIE INC	S	9/17/2014	6/26/2015	9.3
NDA 202714	9	Accelerated Approval Confirmatory Study	CARFILZOMIB	ONYX PHARMACEUTICALS INC	P	1/26/2015	7/24/2015	5.9
NDA 011366	30	New Indication	DICHLORPHENAMIDE	TARO PHARMACEUTICALS USA INC	P	11/10/2014	8/7/2015	8.9
NDA 204242	4	New Indication	BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS	OREXO AB	S	10/10/2014	8/10/2015	10.0
NDA 022272	27	Pediatric	OXYCODONE HCL	PURDUE PHARMA LP	P	12/10/2014	8/13/2015	8.1
NDA 202022	8	Pediatric	RILPIVIRINE	JANSSEN PRODUCTS LP	P	2/27/2015	8/26/2015	5.9
NDA 022416	1	New Indication	SEP-0002093 ESLICARBAZEPINE ACETATE	SUNOVION PHARMACEUTICALS INC	S	10/29/2014	8/27/2015	9.9
NDA 021549	25	Pediatric	APREPITANT	MERCK SHARP AND DOHME CORP	S	7/28/2014	8/28/2015	13.0
NDA 200327	14	New Dosing Regimen	CEFTAROLINE FOSAMIL FOR INJECTION	CEREXA INC	S	11/21/2014	8/31/2015	9.3
NDA 022433	15	New Indication	TICAGRELOR	ASTRAZENECA LP	P	3/6/2015	9/3/2015	6.0
NDA 204412	6	Pediatric	WC3045 (MESALAMINE) DELAYED- RELEASE CAPSULES	WARNER CHILCOTT COMPANY LLC	S	11/12/2014	9/9/2015	9.9
NDA 021602	42	Pediatric	BORTEZOMIB	MILLENNIUM PHARMACEUTICALS INC	P	3/25/2015	9/14/2015	5.7
NDA 207070	1	New Indication	TIOTROPIUM BROMIDE	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	8/15/2014	9/15/2015	13.0

# CY 2015 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals As of December 31, 2015

This report reflects the data shown as it is identified in the database

**Selection Criteria:**

**User Response: Start Date: 1/1/2015 End Date: 12/31/2015**

**Sort Order: Approval Date**

NDA 021652	19	Pediatric	ABACAVIR SULFATE/LAMIVUDINE	VIIV HEALTHCARE CO	S	11/20/2014	9/17/2015	9.9
NDA 022410	20	New Route Of Administration	BUPRENORPHINE AND NALOXONE	INDIVIOR INC	S	4/21/2014	9/22/2015	17.1
NDA 021567	38	New Patient Population	ATAZANAVIR SULFATE	BRISTOL MYERS SQUIBB CO	P	3/27/2015	9/24/2015	6.0
NDA 206352	3	New Patient Population	ATAZANAVIR SULFATE	BRISTOL-MYERS SQUIBB CO	P	3/27/2015	9/24/2015	6.0
NDA 022081	33	New Indication	AMBRISENTAN	GILEAD SCIENCES INC	S	12/5/2014	10/2/2015	9.9
NDA 205123	5	New Dosing Regimen	TMC435 (SIMEPREVIR)	JANSSEN PRODUCTS LP	S	12/12/2014	10/5/2015	9.8
NDA 205123	6	New Indication	TMC435 (SIMEPREVIR)	JANSSEN PRODUCTS LP	S	12/12/2014	10/5/2015	9.8
NDA 205029	1	New Indication	EPINEPHRINE INJECTION	BELCHER PHARMACEUTICALS LLC	S	3/23/2015	10/23/2015	7.0
NDA 205834	2	New Patient Population	LEDIPASVIR AND SOFOBUVIR	GILEAD SCIENCES INC	P	5/14/2015	11/12/2015	6.0
NDA 205834	3	New Indication	LEDIPASVIR AND SOFOBUVIR	GILEAD SCIENCES INC	P	5/15/2015	11/12/2015	6.0
NDA 205834	4	New Dosing Regimen	LEDIPASVIR AND SOFOBUVIR	GILEAD SCIENCES INC	P	5/15/2015	11/12/2015	6.0
NDA 205834	5	New Indication	LEDIPASVIR AND SOFOBUVIR	GILEAD SCIENCES INC	P	5/15/2015	11/12/2015	6.0
NDA 205834	6	New Indication	LEDIPASVIR AND SOFOBUVIR	GILEAD SCIENCES INC	P	5/15/2015	11/12/2015	6.0
NDA 021366	31	Pediatric	ROSUVASTATIN CALCIUM	IPR PHARMACEUTICALS INC	S	10/22/2014	11/20/2015	13.0
NDA 022348	5	Pediatric	IBUPROFEN	CUMBERLAND PHARMACEUTICALS INC	S	1/29/2015	11/20/2015	9.7
NDA 202806	4	Accelerated Approval Confirmatory Study	GSK2118436 (BRAE INHIBITOR)	NOVARTIS PHARMACEUTICALS CORP	P	5/22/2015	11/20/2015	6.0
NDA 204114	4	Accelerated Approval Confirmatory Study	TRAMETINIB	NOVARTIS PHARMACEUTICALS CORP	P	5/22/2015	11/20/2015	6.0

**NDA Efficacy Supplements Approved (SE8)**

APPL NUMBER	SUBM TYPE & NUMBER	SUPPLEMENT TYPE or SUBMISSION CLASS CODE	ESTABLISHED NAME	APPLICANT	PRIORITY REVIEW	RECEIPT DATE	APPROVAL DATE	TOTAL APPROVAL TIME (MONTHS)
NDA 020837	41	Labeling Change With Clinical Data	LEVALBUTEROL HYDROCHLORIDE	OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC	S	3/28/2014	1/22/2015	9.9
NDA 021588	42	Labeling Change With Clinical Data	IMATINIB MESYLATE TABLETS	NOVARTIS PHARMACEUTICALS CORP	S	3/31/2014	1/30/2015	10.0
NDA 201367	3	Labeling Change With Clinical Data	RUFINAMIDE ORAL SUSPENSION	EISAI INC	P	8/12/2014	2/12/2015	6.0
NDA 202293	2	Labeling Change With Clinical Data	DAPAGLIFLOZIN	ASTRAZENECA AB	S	5/12/2014	3/11/2015	10.0
NDA 022037	11	Labeling Change With Clinical Data	GUANFACINE HYDROCHLORIDE	SHIRE DEVELOPMENT INC	S	5/19/2014	3/18/2015	10.0
NDA 202379	16	Labeling Change With Clinical Data	ABIRATERONE ACETATE	JANSSEN BIOTECH INC	S	9/19/2014	3/20/2015	6.0
NDA 020746	32	Labeling Change With Clinical Data	BUDESONIDE	ASTRAZENECA PHARMACEUTICALS LP	S	5/23/2014	3/23/2015	10.0
NDA 022090	11	Labeling Change With Clinical Data	GADOXETATE DISODIUM INJECTION	BAYER HEALTHCARE PHARMACEUTICALS INC	S	5/29/2014	3/27/2015	9.9

**CY 2015 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals  
As of December 31, 2015**

This report reflects the data shown as it is identified in the database

**Selection Criteria:**

**User Response: Start Date: 1/1/2015 End Date: 12/31/2015**

**Sort Order: Approval Date**

NDA 050718	48	Labeling Change With Clinical Data	DOXORUBICIN HYDROCHLORIDE	JANSSEN RESEARCH AND DEVELOPMENT LLC	S	11/4/2014	4/16/2015	5.4
NDA 021743	21	Labeling Change With Clinical Data	ERLOTINIB HCL	OSI PHARMACEUTICALS LLC	P	10/27/2014	4/27/2015	6.0
NDA 021338	5	Labeling Change With Clinical Data	FENTANYL IONTOPHORETIC	THE MEDICINES CO	S	6/30/2014	4/30/2015	10.0
NDA 022334	30	Labeling Change With Clinical Data	EVEROLIMUS	NOVARTIS PHARMACEUTICALS CORP	S	7/28/2014	5/22/2015	9.8
NDA 021356	49	Labeling Change With Clinical Data	TENOFOVIR DISOPROXIL FUMARATE	GILEAD SCIENCES INC	S	8/27/2014	5/29/2015	9.0
NDA 022577	7	Labeling Change With Clinical Data	TENOFOVIR DISOPROXIL FUMARATE	GILEAD SCIENCES INC	S	8/27/2014	5/29/2015	9.0
NDA 020786	33	Labeling Change With Clinical Data	FEXOFENADINE HCL/PSEUDOEPHEDRINE HCL	SANOFI-AVENTIS US LLC	S	8/8/2014	6/8/2015	10.0
NDA 204629	1	Labeling Change With Clinical Data	JARDIANCE	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	8/29/2014	6/26/2015	9.9
NDA 204629	2	Labeling Change With Clinical Data	JARDIANCE	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	9/3/2014	6/26/2015	9.7
NDA 204629	3	Labeling Change With Clinical Data	JARDIANCE	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	9/3/2014	6/26/2015	9.7
NDA 021081	63	Labeling Change With Clinical Data	INSULIN GLARGINE	SANOFI-AVENTIS US LLC	S	9/19/2014	7/17/2015	9.9
NDA 203415	5	Labeling Change With Clinical Data	ENZALUTAMIDE	ASTELLAS PHARMA US INC	S	1/20/2015	7/21/2015	6.0
NDA 021055	10	Labeling Change With Clinical Data	BEXAROTENE	VALEANT PHARMACEUTICALS LUXEMBOURG SARL	S	1/30/2015	7/29/2015	5.9
NDA 202971	6	Labeling Change With Clinical Data	ARIPIRAZOLE EXTENDED RELEASE SUSPENSION FOR INJECTION	OTSUKA PHARMACEUTICAL CO LTD	S	9/30/2014	7/29/2015	9.9
NDA 204790	4	Labeling Change With Clinical Data	DOLUTEGRAVIR (DTG, GSK1349572)	VIIV HEALTHCARE CO	S	10/23/2014	7/30/2015	9.2
NDA 021986	16	Labeling Change With Clinical Data	DASATINIB	BRISTOL-MYERS SQUIBB CO	S	10/14/2014	8/12/2015	9.9
NDA 203389	10	Labeling Change With Clinical Data	CYSTEAMINE BITARTRATE	RAPTOR PHARMACEUTICALS INC	S	7/14/2014	8/14/2015	13.0
NDA 200327	13	Labeling Change With Clinical Data	CEFTAROLINE FOSAMIL FOR INJECTION	CEREXA INC	S	11/14/2014	8/31/2015	9.5
NDA 204042	6	Labeling Change With Clinical Data	CANAGLIFLOZIN (JNJ-28431754)	JANSSEN PHARMACEUTICALS INC	S	9/23/2014	9/10/2015	11.6
NDA 204353	3	Labeling Change With Clinical Data	CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	JANSSEN PHARMACEUTICALS INC	S	9/23/2014	9/10/2015	11.6
NDA 202570	14	Labeling Change With Clinical Data	CRIZOTINIB (PF-02341066)	PF PRISM CV	S	11/14/2014	9/14/2015	10.0
NDA 022334	31	Labeling Change With Clinical Data	EVEROLIMUS	NOVARTIS PHARMACEUTICALS CORP	S	11/20/2014	9/18/2015	9.9

# CY 2015 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals As of December 31, 2015

This report reflects the data shown as it is identified in the database

**Selection Criteria:**

**User Response: Start Date: 1/1/2015 End Date: 12/31/2015**

**Sort Order: Approval Date**

NDA 022200	15	Labeling Change With Clinical Data	EXENATIDE LAR	ASTRAZENECA AB	S	11/24/2014	9/24/2015	10.0
NDA 022200	16	Labeling Change With Clinical Data	EXENATIDE LAR	ASTRAZENECA AB	S	11/24/2014	9/24/2015	10.0
NDA 022200	17	Labeling Change With Clinical Data	EXENATIDE LAR	ASTRAZENECA AB	S	11/24/2014	9/24/2015	10.0
NDA 022200	18	Labeling Change With Clinical Data	EXENATIDE LAR	ASTRAZENECA AB	S	11/24/2014	9/24/2015	10.0
NDA 020845	17	Labeling Change With Clinical Data	NITRIC OXIDE	INO THERAPEUTICS INC	S	12/11/2014	10/9/2015	9.9
NDA 201292	6	Labeling Change With Clinical Data	AFATINIB	BOEHRINGER INGELHEIM	S	5/28/2015	11/9/2015	5.4
NDA 202833	4	Labeling Change With Clinical Data	INGENOL MEBUTATE	LEO PHARMA AS	S	1/20/2015	11/19/2015	10.0
NDA 022458	7	Labeling Change With Clinical Data	PLANT CELL EXPRESSED RECOMBINANT HUMAN G	PFIZER INC	S	1/21/2015	11/20/2015	10.0
NDA 022512	28	Labeling Change With Clinical Data	DABIGATRAN ETEXILATE MESYLATE	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	1/21/2015	11/20/2015	10.0
NDA 203094	3	Labeling Change With Clinical Data	COBICISTAT	GILEAD SCIENCES INC	S	1/27/2015	11/25/2015	9.9

**BLA Efficacy Supplements Approved**

APPL NUMBER	SUBM TYPE & NUMBER	SUPPLEMENT TYPE	PROPER NAME	APPLICANT	PRIORITY REVIEW	RECEIPT DATE	APPROVAL DATE	TOTAL APPROVAL TIME (MONTHS)
BLA 125156	106	EFFICACY	RANIBIZUMAB	GENENTECH, INC.	P	8/7/2014	2/6/2015	6.0
BLA 125527	0	TYPE 9 EFFICACY	NIVOLUMAB	BRISTOL-MYERS SQUIBB COMPANY	P	12/22/2014	3/4/2015	2.4
BLA 125409	104	EFFICACY	PERTUZUMAB	GENENTECH, INC.	S	9/25/2014	3/17/2015	5.7
BLA 125387	48	EFFICACY	AFLIBERCEPT	REGENERON PHARMACEUTICALS, INC.	P	9/30/2014	3/25/2015	5.8
BLA 103353	5183	EFFICACY	FILGRASTIM	AMGEN, INC.	S	9/30/2014	3/30/2015	6.0
BLA 103000	5282	EFFICACY	ONABOTULINUMTOXINA	ALLERGAN, INC.	S	6/17/2014	4/17/2015	10.0
BLA 125477	11	EFFICACY	RAMUCIRUMAB	ELI LILLY AND COMPANY	S	2/18/2015	4/24/2015	2.1
BLA 125338	85	EFFICACY	CLOSTRIDIAL COLLAGENASE	AUXILIUM PHARMACEUTICALS, INC.	S	7/15/2014	5/15/2015	10.0
BLA 125338	87	EFFICACY	CLOSTRIDIAL COLLAGENASE	AUXILIUM PHARMACEUTICALS, INC.	S	7/15/2014	5/15/2015	10.0
BLA 125338	88	EFFICACY	CLOSTRIDIAL COLLAGENASE	AUXILIUM PHARMACEUTICALS, INC.	S	7/15/2014	5/15/2015	10.0
BLA 125274	102	EFFICACY	ABOBOTULINUMTOXINA	IPSEN BIOPHARM LIMITED	C	9/15/2014	7/15/2015	10.0
BLA 103951	5363	EFFICACY	DARBEPOETIN ALFA	AMGEN, INC.	S	9/24/2014	7/23/2015	9.9
BLA 125433	14	EFFICACY	GOLIMUMAB FOR INFUSION	JANSSEN BIOTECH, INC.	S	10/6/2014	8/5/2015	10.0
BLA 125388	80	EFFICACY	BRENTUXIMAB VEDOTIN	SEATTLE GENETICS, INC.	P	2/18/2015	8/17/2015	5.9
BLA 125057	393	EFFICACY	ADALIMUMAB	ABBVIE INC.	S	11/10/2014	9/9/2015	10.0

**CY 2015 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals  
As of December 31, 2015**

This report reflects the data shown as it is identified in the database

**Selection Criteria:**

**User Response: Start Date: 1/1/2015 End Date: 12/31/2015**

**Sort Order: Approval Date**

BLA 125418	33	EFFICACY	ZIV-AFLIBERCEPT	SANOFI-AVENTIS U.S. LLC	S	6/25/2015	9/17/2015	2.8
BLA 103471	5186	EFFICACY	INTERFERON BETA-1B	BAYER HEALTHCARE PHARMACEUTICALS INC.	S	11/25/2014	9/25/2015	10.0
BLA 125554	2	EFFICACY	NIVOLUMAB	BRISTOL-MYERS SQUIBB COMPANY	P	3/30/2015	9/30/2015	6.0
BLA 125514	5	EFFICACY	PEMBROLIZUMAB	MERCK SHARP & DOHME CORP.	P	4/2/2015	10/2/2015	6.0
BLA 125554	5	EFFICACY	NIVOLUMAB	BRISTOL-MYERS SQUIBB COMPANY	P	7/2/2015	10/9/2015	3.3
BLA 125377	73	EFFICACY	IPILIMUMAB	BRISTOL-MYERS SQUIBB COMPANY	S	12/29/2014	10/28/2015	10.0
BLA 125031	180	EFFICACY	PEGFILGRASTIM	AMGEN, INC.	P	2/13/2015	11/13/2015	9.0
BLA 125057	394	EFFICACY	ADALIMUMAB	ABBVIE INC.	S	12/18/2014	11/23/2015	11.2
BLA 125554	1	EFFICACY	NIVOLUMAB	BRISTOL-MYERS SQUIBB COMPANY	P	2/27/2015	11/23/2015	8.8
BLA 125554	12	EFFICACY	NIVOLUMAB	BRISTOL-MYERS SQUIBB COMPANY	P	9/16/2015	11/23/2015	2.2
BLA 125514	4	EFFICACY	PEMBROLIZUMAB	MERCK SHARP & DOHME CORP.	P	3/25/2015	12/18/2015	8.8
BLA 125514	6	EFFICACY	PEMBROLIZUMAB	MERCK SHARP & DOHME CORP.	P	6/19/2015	12/18/2015	6.0
BLA 125360	67	EFFICACY	INCOBOTULINUMTOXINA	MERZ PHARMACEUTICALS GMBH	S	2/23/2015	12/22/2015	9.9